Our use of CRISPR/Cas9 to delete H-2Kb from tumor cells proved that, despite class I MHC expression being low on IFN-γ-signaling-mutant tumor cells, H-2Kb was nonetheless required for anti-PD-L1 efficacy and CD8+ T cell-mediated tumor control in vivo. Here, HLA-C is linked to neoplasm.